Combined antihypertensive therapy in treating patients with metabolic syndrome
Abstract
Aim. To study the effects of 24-week treatment with trandolapril, as monotherapy or combined with verapamil, on parameters of 24-hour blood pressure monitoring (BPM), carbohydrate, lipid, and purine metabolism, tissue insulin sensitivity and microalbuminuria (MAU) in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS).
Material and methods. The study included 20 patients with Stage I-II AH and MS. Initial dose of trandolapril was 2 mg/d, administered in the morning. If needed, trandolapril dose was doubled one week later. One more week later, all patients not achieving target BP levels were administered verapamil SR (240 mg/d). At baseline and 24 weeks after therapy start, levels of MAU, carbohydrate and lipid metabolism, 24-hour BPM were measured.
Results. Six patients achieved target BP levels receiving trandolapril monotherapy only (4 mg/d). For 14 participants, additional treatment with verapamil SR (240 mg/d) was necessary for achieving target BP levels. Fasting glucose and postprandial C-reactive protein levels significantly decreased (p<0,05), as well as the levels of total cholesterol (CH) and low-density lipoprotein CH. MAU levels were similar to baseline parameters: 13,0+5,8 and 12,9+4,33 mg/1.
Conclusion. Trandolapril and verapamil combination, being metabolically neutral, demonstrated good antihypertensive effects and improvement of carbohydrate and lipid metabolism parameters.
About the Authors
V. B. Mychka
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
N. V. Flegontova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
K. P. Ivanov
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
G. Kh. Sharipova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
I. E. Chazova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
References
1. Dahlof В., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bend-oflumethiazide as required, in the ASCOT-BPLA: a multicenter randomized controlled trial. Lancet 2005; 366: 895-906.
2. Giverts M.M. Manipulation of the renin-angiotensin system. Circulation 2001; 104(5): 14-8.
3. Lender D., Arauz-Pacheco C., Breen L. et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertension 1999; 12: 298-303.
4. Kannel W.B. Potency of vascular risk factors as the basic for antihypertensive therapy. Eur Heart J 1992; 13: 34-2.
5. Maarek M. Efficacite et tolerance du trandolapril chez l'hypertendu en surpoids. Ann Cardiol Angeiol 1996; 45(6): 343-51.
6. Adalet K. Trandolapril in overweight patients with mild-to-moderate essential hypertension: The Turkish multicenter study. Current therap res 1996; 57(12): 980-8.
7. Dahlof B., Sever P.S., Poulter N.R. et al, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendofiumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
8. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.
9. Griendling K.K., Minieri C.A., Ollerenshow J.D. et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74(6): 1141-8.
10. Plosker G.L., Sorcin E.M. Quinapril: a review of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994 Aug; 48(2): 227-52.
11. Lender D., Arauz-Pacheco C., Breen L. et al. A Double Blind Comparison of the Effect of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. Am J Hypertens 1999; 12: 298-303.
12. Ruilope L.M., de la Sierra A., Moreno E. et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patiens uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999; 17: 1917-23.
13. Fernandes R., Puig J.G., Rodriguez-Perez J.C. et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patiens with albuminuria: a randomised, double-blind stude. J Human Hypertens 2001; 15: 849-56.
14. Ruggenenti P. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.
Review
For citations:
Mychka V.B., Flegontova N.V., Ivanov K.P., Sharipova G.Kh., Chazova I.E. Combined antihypertensive therapy in treating patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2008;7(3):24-30. (In Russ.)
Views:
480
Email this article 
